- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, July 12, 2019
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
An article appearing in The New York Times cited a study published in The American Journal of Managed Care® (AJMC®). Researchers of the study, “Improving Provider Directory Accuracy: Can Machine-Readable Directories Help?,” examined the accuracy of provider directories and found widespread errors, leading them to conclude that machine-readable directories are not more accurate than conventional directories, despite their advantages. The study was also highlighted by Becker’s Hospital Review.
A Forbes article on biosimilars referred to an article from AJMC®’s sister site The Center for Biosimilars®. The article, “Biologics Are Not Monopolies to Be Regulated, AEI Economists Assert,” covered a blog post by 2 economists from the American Enterprise Institute in which they shot back at the idea that biosimilars are natural monopolies and should have their prices regulated by the government, which was proposed by critics a few months prior.
The Health Affairs blog referenced an AJMC® published study from May. The study, "Producing Comparable Cost and Quality Results From All-Payer Claims Databases," described a replicable process for standardizing disparate databases and methods to calculate cost and quality measures within and across states.
The AJMC® published study “Pharmacogenetic-Guided Psychiatric Intervention Associated With Increased Adherence and Cost Savings” was cited in an article from The Doctor Weighs In. According to the 2014 study, the data show the utility of pharmacogenetic testing in everyday psychiatric clinical practice, as it can lead to improved patient adherence and decreased healthcare costs.
The National Pharmaceutical Council’s Tuesday CER Daily Newsfeed included AJMC®’s article “Despite Growth, Uptake of Downside Risk in ACO Contracts Remains Low,” which covered a study that found in 2018, 33% of accountable care organizations assumed downside risk, up from 28% in 2012.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Covered Preventive Services at Risk: V-BID Summit Breaks Down the Braidwood v Becerra Case
March 20th 2024For more than a decade, certain high-value preventive care services have been covered at no cost to patients under the Affordable Care Act, but a current legal challenge has the coverage at risk.
Read More
Reducing Low-Value Care Is Hard, but What About Just Not Paying for It?
March 14th 2024After years of efforts to reduce low-value care, panelists at the 2024 Value-Based Insurance Design Summit proposed a new strategy: drawing a line in the sand that payers will not be on the hook for these services.
Read More
